摘要
目的:探讨心舒宝胶囊联合比索洛尔对冠心病心绞痛患者血管内皮功能,血清不规则趋化因子(Fractalkine)、血小板活化因子(PAF)和脂蛋白相关性磷脂酶A2(Lp-PLA2)的影响。方法:选取2018年2月至2021年2月南京医科大学附属脑科医院心内科收治的冠心病心绞痛患者132例,根据随机数字表法分为观察组(n=66)和对照组(n=66)。对照组患者采用比索洛尔治疗,观察组患者采用心舒宝胶囊联合比索洛尔治疗。观察两组患者的治疗效果,治疗前后心绞痛发作次数、持续时间,治疗前后内皮素-1(ET-1)、一氧化氮(NO)、血栓素A2(TXA2)和血栓素B2(TXB2)水平,以及血清Fractalkine、PAF和Lp-PLA2水平的变化,记录两组患者不良反应发生情况。结果:观察组患者的心绞痛治疗总有效率为87.88%(58/66),高于对照组的72.73%(48/66);观察组患者的心电图治疗总有效率为80.30%(53/66),高于对照组的63.64%(42/66),差异有统计学意义(P<0.05)。观察组患者硝酸甘油用量少于对照组;观察组患者治疗后的心绞痛发作次数少于治疗前和对照组,持续时间短于治疗前和对照组,差异均有统计学意义(P<0.05)。观察组患者治疗后的ET-1、TXA2和TXB2水平低于治疗前和对照组,血清NO水平高于治疗前和对照组,差异均有统计学意义(P<0.05)。观察组患者治疗后的血清Fractalkine、PAF和Lp-PLA2水平低于治疗前和对照组,差异均有统计学意义(P<0.05)。观察组患者不良反应发生率为7.58%(5/66),与对照组(4.55%,3/66)比较,差异无统计学意义(P>0.05)。结论:冠心病心绞痛患者采用心舒宝胶囊联合比索洛尔治疗,能有效改善心绞痛、心电图疗效和血管内皮功能,进一步下调血清Fractalkine、PAF和Lp-PLA2水平,且安全性高。
OBJECTIVE:To probe into the effect of Xinshubao capsule combined with bisoprolol on vascular endothelial function and serum Fractalkine(Fractalkine),platelet activating factor(PAF)and lipoprotein-associated phospholipase A2(Lp-PLA2)in patients with angina pectoris of coronary heart disease.METHODS:Totally 132 patients with angina pectoris of coronary heart disease admitted to the cardiology department of Brain Hospital Affiliated to Nanjing Medical University from Feb.2018 to Feb.2021 were selected to be divided into observation group(n=66)and control group(n=66)via the random number table.The control group was treated with bisoprolol,and the observation group was given Xinshubao capsule combined with bisoprolol.The therapeutic effects,the frequency and duration of angina pectoris attacks,the changes of endothelin-1(ET-1),nitric oxide(NO),thromboxane A2(TXA2),thromboxane B2(TXB2)and serum Fractalkine,PAF and Lp-PLA2 levels were observed before and after treatment,and the incidences of adverse drug reactions of the two groups were recorded.RESULTS:The total effective rate of angina pectoris in the observation group was 87.88%(58/66),higher than 72.73%(48/66)in the control group;the total effective rate of electrocardiogram in the observation group was 80.30%(53/66),higher than 63.64%(42/66)in the control group,with statistically significant difference(P<0.05).The dosage of nitroglycerin in the observation group was lower than that in the control group;the frequency of angina pectoris attacks and the duration in the observation group after treatment were lower and shorter than those before treatment and in the control group,with statistically significant differences(P<0.05).After treatment,the ET-1,TXA2 and TXB2 levels in the observation group were lower than those before treatment and in the control group,and the serum NO level was higher than that before treatment and in the control group,with statistically significant differences(P<0.05).The serum Fractalkine,PAF and Lp-PLA2 levels in the observation group after treatment were lower than those before treatment and in the control group,with statistically significant differences(P<0.05).The incidences of adverse drug reactions in the observation group was 7.58%(5/66),which had no statistical significance in comparison with 4.55%(3/66)in the control group(P>0.05).CONCLUSIONS:Patients with angina pectoris of coronary heart disease treated with Xinshubao capsule combined with bisoprolol can effectively improve the angina pectoris,efficacy of electrocardiogram and vascular endothelial function,and further down-regulate the serum Fractalkine,PAF and Lp-PLA2 levels,with high safety.
作者
戴海云
黄雷
DAI Haiyun;HUANG Lei(Dept.of Cardiology,Brain Hospital Affiliated to Nanjing Medical University,Nanjing 210000,China;Dept.of Cardiology,Nanjing Chest Hospital,Nanjing 210029,China)
出处
《中国医院用药评价与分析》
2022年第7期791-795,共5页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
江苏省自然科学基金项目(No.BK20182490)。
